People of Vcare adhere to the concept of "The better Care, The better Medicines", pay attention to quality, enhance their own value, and lay the foundation for the company's long-term development. People of Vcare pay attention to innovation, improve core competitiveness, and contribute to the development of the pharmaceutical industry. Vcare devotes itself to drug research and development with independent intellectual property rights and closely integrate advanced chemical technology with global market demand. Vcare makes full use of advantages in scientific and technological research and development, and gradually turn our brilliant business blueprint into reality. In the development wave of the pharmaceutical and health industry, Vcare will ride the waves and stand at the forefront!

Welcome to visit Vcare!

▪ Ph.D. in Medicinal Chemistry, China Pharmaceutical University; Ph.D. in Chemistry, École Normale Supérieure Paris-Saclay, France

▪ Industry Professor at China Pharmaceutical University; Jiangsu Innovation and Entrepreneurship Doctor; Innovative Entrepreneurs of Zijin Mountain Talent Pioneer Program; Senior Engineer

▪ Overall responsibility for corporate strategic planning, administration and operation

▪ Over 20 years of experience in innovative drug R&D and management; once worked as a visiting scholar at GSK RTP R&D Center in North Carolina, USA

▪ Ph.D., China Pharmaceutical University

▪ Responsible for innovative drug molecular design, compound screening and pre-clinical development of the Company

▪ Over 20 years of experience in innovative drug design and discovery; inventor of core products VC005 and Eratrectinib

▪ Previously served at pharmaceutical enterprises including Beijing Hanmi Pharmaceutical Co., Ltd. and Shanghai Allist Pharmaceuticals Co., Ltd.,where participating in molecular structure design and is named as an inventor of the patented marketed drug Firmonertinib. He has driven two small-molecule innovative drugs to marketing approval, with extensive practical experience in drug design and industrial transformation.

▪ Master’s Degree, Nanjing University of Chinese Medicine

▪ Responsible for clinical development of the Company’s innovative drugs

▪ Over 20 years of experience in clinical development of small-molecule innovative drugs. She has led the clinical development of all of our Core Products,and spearheaded the pivotal clinical trials and marketing approval of the Company’s first-in-house innovative drug, Eratrectinib.